PT-2385

PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM[1][2].

Product Specifications

CAS Number

[1672665-49-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PT-2385.html

Purity

99.95

Solubility

DMSO : ≥ 50 mg/mL

Smiles

N#CC1=CC(F)=CC(OC2=CC=C(S(=O)(C)=O)C3=C2CC(F)(F)[C@H]3O)=C1

Molecular Formula

C17H12F3NO4S

Molecular Weight

383.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Eli Wallace, Ph.D. PT2385: HIF-2α Antagonist for the Treatment of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016.|[2]Xie C, et al. Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23 (11) :1298-1308.|[3]Wallace EM, et al. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma. Cancer Res. 2016 Sep 15;76 (18) :5491-500.